News

First FDA cleared smart cap and mobile app to combat hair loss

DURHAM, NC – April 2, 2019 – PhotonMD, Inc., an innovative photomedicine device company, announced its REVIAN RED system, an FDA cleared, over-the-counter (OTC) light therapy system for the treatment of androgenetic alopecia in both men and women is now shipping to customers.

“We have been greatly encouraged by the enthusiasm surrounding the launch of REVIAN RED and are excited to offer our treatment solution to help the 80 million Americans living with androgenetic alopecia, or pattern hair loss. It is important to give patients a convenient, effective, and safe solution without negative side effects for this chronic and progressive condition,” states President and Chief Executive Officer, Dr. Nicholas Medendorp, Jr.

The REVIAN RED system uses a wireless smart Cap and companion mobile app controller to stimulate natural hair growth in just 10-minutes a day. The revolutionary medical device combines a proprietary application of specific wavelengths of light with a first-of-its-kind smartphone mobile app (iOS or Android) allowing patients to control, schedule and monitor their daily 10-minute treatments for an effortless regrowth experience.

“The REVIAN RED system is offered at $749 and is an exceptional choice for men and women who are seeking a chemical-free hair growth solution in the privacy of their own home with zero mess or side effects,” said Medendorp.

REVIAN RED is available with a special launch discount for a limited time at REVIAN .com through its secure and simple checkout process. Restore your hair and your confidence. REVIAN .com

About PhotonMD:

PhotonMD is a modern medical device company focused on identifying and developing natural, chemical free, non-UV containing light technologies that will enable the treatment of chronic diseases. The products treat various health conditions using Modulated Light Therapy™ (MLT) technology that play an important role in unlocking key elements in human physiology. The company is dedicated to pushing the boundaries of scientific research around light-based therapy and designing innovative and safe solutions that dramatically improve the lives of patients. For more information about PhotonMD, please visit PhotonMD.com.

Forward-looking Statements:

Except for historical information, all the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: reliance on key personnel; the early stage of our business; risks associated with the medical device development processes; competition; and other risks described in other Company press releases and presentations. PhotonMD assumes no obligation and do not intend to update these forward-looking statements, except as required by law.

Media Contact:

Steve Zarnosky
media@photonmd.com
919.229.4653

First OTC medical device that combats hair loss and empowers consumer compliance

DURHAM, NC – February 7, 2019 – PhotonMD, Inc., an innovative photomedicine device company, announced the U.S. Food and Drug Administration (FDA) has granted clearance for the company’s first Modulated Light Therapy™ (MLT) product, the REVIAN RED system, over-the-counter (OTC) light therapy system for the treatment of androgenetic alopecia in both men and women.

The REVIAN RED system uses a wireless smart Cap and companion mobile app controller to stimulate natural hair growth in just 10-minutes a day. The revolutionary medical device combines a proprietary application of specific wavelengths of light with a first-of-its-kind smartphone mobile app (iOS or Android) allowing patients to control, schedule and monitor their daily 10-minute treatments for an effortless regrowth experience.

“More than 80 million Americans suffer from androgenetic alopecia, or pattern hair loss, and spend $3.5 billion annually on ineffective treatments. There is an unmet need for an easy to use, effective, at-home treatment option, without negative side effects,” states President and Chief Executive Officer, Dr. Nicholas Medendorp, Jr. “After years of research and development, we are proud to reveal REVIAN , an at-home smart Cap and mobile app that empowers users to treat, track and take accountability for stopping their hair loss.”

The lightweight REVIAN Cap applies comfort and superior science through its patent-pending MLT technology that enhances the body’s natural healing through precise intensity, dose and multiple wavelengths of LED light. It communicates wirelessly with the free REVIAN mobile app that syncs with the Cap to control treatments, document visual progress, track treatment status and schedule reminders.

“The clearance of the REVIAN RED system in the U.S. is a milestone in the progress of light-based therapies and is expected to deliver improvement in the efficacy, value and choices offered to patients as a home-based androgenetic alopecia solution for male and female pattern hair loss,” said Medendorp. “As we bring REVIAN to market, we intend to continue to develop innovative photomedicine therapeutic solutions for treating other chronic diseases and clinical conditions susceptible to light-based healing.”

The REVIAN RED system is available for pre-order and is expected to ship to consumers in April 2019. In just ten minutes a day, REVIAN stimulates chemical-free hair growth with uniform coverage that repairs and grows hair cells, all in the privacy of the patient’s home with zero pain or downtime. Restore your hair. And your life. REVIAN .com

About PhotonMD:

PhotonMD is a modern medical device company focused on identifying and developing natural, chemical free, non-UV containing light technologies that will enable the treatment of chronic diseases. The products treat various health conditions using Modulated Light Therapy™ (MLT) technology that play an important role in unlocking key elements in human physiology. The company is dedicated to pushing the boundaries of scientific research around light-based therapy and designing innovative solutions to help dramatically improve people’s lives. For more information about PhotonMD, please visit PhotonMD.com.

Forward-looking Statements:

Except for historical information, all the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: reliance on key personnel; the early stage of our business; risks associated with the medical device development processes; competition; and other risks described in other Company press releases and presentations. PhotonMD assumes no obligation and do not intend to update these forward-looking statements, except as required by law.

Media Contact:

Steve Zarnosky
media@photonmd.com
919.229.4653